AR007030A1 - Un compuesto derivado de indol, su uso, un procedimiento para producirlo, y una composicion farmaceutica que lo contiene - Google Patents

Un compuesto derivado de indol, su uso, un procedimiento para producirlo, y una composicion farmaceutica que lo contiene

Info

Publication number
AR007030A1
AR007030A1 ARP970101888A ARP970101888A AR007030A1 AR 007030 A1 AR007030 A1 AR 007030A1 AR P970101888 A ARP970101888 A AR P970101888A AR P970101888 A ARP970101888 A AR P970101888A AR 007030 A1 AR007030 A1 AR 007030A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkenyl
optionally substituted
mar1
conh
Prior art date
Application number
ARP970101888A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR007030A1 publication Critical patent/AR007030A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Compuestos de fórmula I y sus derivados farmacéuticamente aceptables donde R1 y R2 son sustituyentes opcionales y representan independientemente alquiloC1-6, alquenilo C1-6, alquenilo C2-6 [opcionalmente sustituído con C02H o CO2 (alquilo C1-6)],alquinilo C2-6, halógeno, perfluoralquilo C1-3, (CH2)mAr1,(CH2)mHet, donde R1 y R2 son sustituyentes opcionales y representan independientemente alquilo C1-6, alquenilo C1-6, alquenilo C2-6 [opcionalmentesustituido con CO2H o CO2(alquiloC1-6)], alquinilo C2-6, halógeno, perfluoralquilo C1-3, (CH2)mAr1, (CH2)mHet1, (CH2)mCONR7R8, (CH2)mCO2R8,O(CH2)qCO2R8, (CH2)mCOR8,(CH2)mOR8, O(CH2)pOR8, (CH2)mNR7R8, (CH2)mCN,S(O)nR8, SO2NR7R8, CONH(CH2)mAr1 o CONH(CH2)mHet1; R3 es H,a lquilo C1-6, (CH2)pNR9R10,SO2R10, SO2NR9R10, (CH2)mCOR10, alquenilo C2-6, alquinilo C2-6, (CH2)mCONR9R10, (CH2)mCO2R1O(CH2)pCN, (CH2)pR10 o (CH2)pOR10; R4 es H o alquilo C1-6; R5 es H oOH; R6 es fenilo opcionalmente condensado con un anilloheterocíc lico saturado, estando el grupo en su totalidad opcionalmente sustituido; R7-10 se definen ensu totalidad en la presente y pueden ser Ar2 o Het2; Z es CO2H, CONH(tetrazol) -5-ilo), CONHSO2O(alquilo C1-4); CO2Ar3, CO2(alquilo C1-6),tetrazol-5-ilo,CO NHSO2Ar3, CONHSO2(CH2)qAr3 o CONHSO2(alquilo C1-6); Ar1-3 es independientemente fenilo, naftilo o un anillo heterociclo aromático, gruposque están opcionalmente condensados y opcionalmente sustituidos; y Het1 yHet2 son independient emente un heterociclo no aromático que está opcionalmentesustituido; útiles en el tratamiento de la restenosis, la insuficiencia renal la hipertensión pulmonar.
ARP970101888A 1996-05-09 1997-05-07 Un compuesto derivado de indol, su uso, un procedimiento para producirlo, y una composicion farmaceutica que lo contiene AR007030A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9609641.7A GB9609641D0 (en) 1996-05-09 1996-05-09 Compounds useful in therapy

Publications (1)

Publication Number Publication Date
AR007030A1 true AR007030A1 (es) 1999-10-13

Family

ID=10793387

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970101888A AR007030A1 (es) 1996-05-09 1997-05-07 Un compuesto derivado de indol, su uso, un procedimiento para producirlo, y una composicion farmaceutica que lo contiene

Country Status (43)

Country Link
US (4) US6017945A (es)
EP (1) EP0901470B1 (es)
JP (1) JP3245179B2 (es)
KR (1) KR100331217B1 (es)
CN (1) CN1124262C (es)
AP (1) AP830A (es)
AR (1) AR007030A1 (es)
AT (1) ATE263151T1 (es)
AU (1) AU717849B2 (es)
BG (1) BG102873A (es)
BR (1) BR9709072A (es)
CA (1) CA2253876A1 (es)
CO (1) CO4650036A1 (es)
CZ (1) CZ292928B6 (es)
DE (1) DE69728392T2 (es)
DK (1) DK0901470T3 (es)
DZ (1) DZ2227A1 (es)
EA (1) EA001471B1 (es)
ES (1) ES2218675T3 (es)
GB (1) GB9609641D0 (es)
HK (1) HK1019149A1 (es)
HN (1) HN1997000058A (es)
HR (1) HRP970249B1 (es)
HU (1) HUP9901245A3 (es)
ID (1) ID16878A (es)
IL (1) IL125903A0 (es)
IS (1) IS1856B (es)
MA (1) MA26428A1 (es)
NO (1) NO312547B1 (es)
NZ (1) NZ332640A (es)
OA (1) OA10896A (es)
PE (1) PE65098A1 (es)
PL (1) PL329725A1 (es)
PT (1) PT901470E (es)
SI (1) SI0901470T1 (es)
SK (1) SK150398A3 (es)
TN (1) TNSN97078A1 (es)
TR (1) TR199802269T2 (es)
TW (1) TW491838B (es)
UA (1) UA50767C2 (es)
UY (1) UY24546A1 (es)
WO (1) WO1997043260A1 (es)
ZA (1) ZA973963B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9722287D0 (en) 1997-10-22 1997-12-17 Pfizer Ltd Compounds useful in therapy
US7074800B1 (en) * 1999-02-10 2006-07-11 Astrazeneca Ab Quinazoline derivatives as angiogenesis inhibitors
GB0016162D0 (en) * 2000-06-30 2000-08-23 Cancer Res Campaign Tech Indole-3-acetic acid derivatives
US20050203166A1 (en) * 2000-06-30 2005-09-15 Cancer Research Technology Limited Indole-3-acetic acid derivatives
TWI224101B (en) 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
PT1397130E (pt) 2001-06-20 2007-11-13 Wyeth Corp Derivados ácidos de indole substituído como inibidores de inibidor 1 do activador de plasminogénio (pai-1)
AR037097A1 (es) 2001-10-05 2004-10-20 Novartis Ag Compuestos acilsulfonamidas, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento
MXPA05006282A (es) 2002-12-10 2005-08-19 Wyeth Corp Derivados del acido 1h-indol-1-il acetico de 3-alquilo y 3-arilalquilo sustituido como inhibidores del inhibidor-1 de activador de plasminogeno (pai-1).
AU2003296324A1 (en) 2002-12-10 2004-06-30 Wyeth Aryl, aryloxy, and alkyloxy substituted 1h-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
UA80453C2 (en) 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
BR0316584A (pt) 2002-12-10 2005-10-04 Wyeth Corp Derivados de ácido acético indol oxo-acetil amino substituìdo como inibidores do inibidor-1 do ativador do plasminogênio (pai-1)
CN1726190A (zh) 2002-12-10 2006-01-25 惠氏公司 作为纤溶酶原激活物抑制剂-1(pai-1)的抑制剂的取代3-羰基-1h-吲哚-1-基乙酸衍生物
JP2007500253A (ja) * 2003-01-22 2007-01-11 イーライ リリー アンド カンパニー ステロイドホルモン核内受容体のインドール誘導体モジュレーター
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US7446201B2 (en) 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7582773B2 (en) 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7163954B2 (en) 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7420083B2 (en) 2003-09-25 2008-09-02 Wyeth Substituted aryloximes
US7265148B2 (en) 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7351726B2 (en) 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7141592B2 (en) 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7332521B2 (en) 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7342039B2 (en) 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
JP2005109006A (ja) * 2003-09-29 2005-04-21 Tdk Corp 高電圧貫通型コンデンサ及びマグネトロン
HN2004000536A (es) * 2003-12-16 2009-02-18 Wyeth Corp Un procediemiento de sintesis para la alquilacion reductiva de la posicon c-3 de indoles
CN101039936A (zh) 2004-08-23 2007-09-19 惠氏公司 作为i-型纤溶酶原激活剂抑制剂(pai-1)调节剂用于治疗血栓形成和心血管疾病的唑基-萘基酸
AU2006279496A1 (en) 2005-08-17 2007-02-22 Wyeth Substituted indoles and use thereof
KR20080111137A (ko) * 2006-04-13 2008-12-22 액테리온 파마슈티칼 리미티드 초기 단계 특발성 폐 섬유증을 위한 엔도텔린 수용체 대항제
DE102008030206A1 (de) 2008-06-25 2009-12-31 Bayer Schering Pharma Aktiengesellschaft 3-Cyanoalky- und 3-Hydroxyalkyl-Indole und ihre Verwendung
DE102008030207A1 (de) 2008-06-25 2009-12-31 Bayer Schering Pharma Aktiengesellschaft Substituierte 7-Sulfanylmethyl-, 7-Sulfinylmethyl- und 7-Sulfonylmethyl-Indole und ihre Verwendung
CN106674065A (zh) * 2016-12-07 2017-05-17 贵州大学 一种5‑卤代‑2‑烷氧基‑4‑甲苯磺酰氯制备方法
GB201817038D0 (en) * 2018-10-19 2018-12-05 Inflazome Ltd Novel processes
BR112021016620A2 (pt) 2019-02-27 2021-11-03 Univ California Azepino-indóis e outros heterociclos para o tratamento de distúrbios cerebrais

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL297887A (es) * 1962-09-14
DE1950346B2 (de) * 1968-10-08 1973-06-28 Sumitomo Chemical Co 2-indolylessigsaeureverbindungen und diese verbindungen enthaltende arzneipraeparate
US4397079A (en) * 1981-03-30 1983-08-09 International Business Machines Corp. Process for improving the yield of integrated devices including Schottky barrier diodes
US5245046A (en) * 1988-11-14 1993-09-14 The Upjohn Company α-amino-indole-3-acetic acids useful as anti-diabetic, anti-obesity and anti-atherosclerotic agents
US5468898A (en) * 1990-09-10 1995-11-21 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted naphthylene compounds exhibiting selective leukotriene B4 antagonist activity
ZA939516B (en) * 1992-12-22 1994-06-06 Smithkline Beecham Corp Endothelin receptor antagonists
ES2141197T3 (es) * 1993-03-19 2000-03-16 Merck & Co Inc Derivados del acido fenoxifenilacetico.
GB9317096D0 (en) * 1993-08-17 1993-09-29 Pfizer Ltd Indoles

Also Published As

Publication number Publication date
US6136843A (en) 2000-10-24
AU2697897A (en) 1997-12-05
BR9709072A (pt) 1999-08-03
NO985225D0 (no) 1998-11-09
UA50767C2 (uk) 2002-11-15
SI0901470T1 (en) 2004-08-31
AP830A (en) 2000-05-03
HUP9901245A3 (en) 2002-01-28
CO4650036A1 (es) 1998-09-03
NZ332640A (en) 2001-03-30
BG102873A (en) 1999-11-30
JP3245179B2 (ja) 2002-01-07
JPH11508285A (ja) 1999-07-21
IS4838A (is) 1998-08-28
ES2218675T3 (es) 2004-11-16
HK1019149A1 (en) 2000-01-14
US6384070B2 (en) 2002-05-07
ATE263151T1 (de) 2004-04-15
KR100331217B1 (ko) 2002-05-09
MA26428A1 (fr) 2004-12-20
HRP970249B1 (en) 2003-06-30
HN1997000058A (es) 1997-06-26
CN1216531A (zh) 1999-05-12
US6017945A (en) 2000-01-25
DK0901470T3 (da) 2004-07-12
PE65098A1 (es) 1998-10-29
TR199802269T2 (xx) 2001-12-21
EP0901470A1 (en) 1999-03-17
AP9700982A0 (en) 1997-07-31
SK150398A3 (en) 1999-03-12
OA10896A (en) 2001-10-11
ZA973963B (en) 1998-11-09
PL329725A1 (en) 1999-04-12
US6306852B1 (en) 2001-10-23
DE69728392D1 (de) 2004-05-06
EP0901470B1 (en) 2004-03-31
ID16878A (id) 1997-11-20
CN1124262C (zh) 2003-10-15
NO312547B1 (no) 2002-05-27
IS1856B (is) 2003-02-21
KR20000010879A (ko) 2000-02-25
UY24546A1 (es) 2000-09-29
TNSN97078A1 (fr) 2005-03-15
IL125903A0 (en) 1999-04-11
AU717849B2 (en) 2000-04-06
PT901470E (pt) 2004-07-30
CA2253876A1 (en) 1997-11-20
EA199800908A1 (ru) 1999-06-24
DZ2227A1 (fr) 2002-12-25
CZ292928B6 (cs) 2004-01-14
NO985225L (no) 1998-11-09
GB9609641D0 (en) 1996-07-10
TW491838B (en) 2002-06-21
CZ358298A3 (cs) 1999-08-11
EA001471B1 (ru) 2001-04-23
US20010014677A1 (en) 2001-08-16
WO1997043260A1 (en) 1997-11-20
HUP9901245A2 (hu) 1999-08-30
HRP970249A2 (en) 1998-06-30
DE69728392T2 (de) 2005-01-13

Similar Documents

Publication Publication Date Title
AR007030A1 (es) Un compuesto derivado de indol, su uso, un procedimiento para producirlo, y una composicion farmaceutica que lo contiene
CA2236814A1 (en) Quinoline and quinazoline compounds useful in therapy
KR920008063A (ko) 전립선 이상비대 치료용 아자스테로이드 화합물, 그것의 제조방법 및 용도
FI930970A0 (fi) Imidazolderivat med bifenylsulfonylurea- eller bifenylsulfonyluretansidokedja, foerfaranden foer framstaellning av dessa och anvaendning av dessa
TR200000447T2 (tr) 5-Alkil-2-arilaminofenilasetik asitler ve türevleri.
ATE117999T1 (de) Zentralnervensystem wirksame chromanderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen.
BR9307580A (pt) Compostos processo para a preparação dos mesmos composições farmacêuticas uso de um composto e processo de tratamento de um mamífero que inclui o ser humano
AR012732A1 (es) Derivados de fenilquinolinas, procedimientos para su preparacion, composiciones farmaceuticas, y su uso para la fabricacion de medicamentos
PE20000329A1 (es) Derivados de indol y composiciones farmaceuticas que los contienen
NO175254C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive derivater av N-sulfonylindolin
ES2160649T3 (es) Nuevos compuestos lactamicos y procedimientos para su preparacion.
AR023111A1 (es) Derivados de sulfonamida utiles como antagonistas del receptor 5-ht7, un procedimiento para su preparacion y composicion farmaceutica que los comprenden
NO177995C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 1,3-dioksanderivater
ES557600A0 (es) Procedimiento para preparar 2,4-difenil-1,3-dioxanos
AR020773A1 (es) Compuesto derivados de 3-(tetrahidropiridin-4-il)indol, metodo para prepararlo, una composicion farmaceutica que los contiene, metodo para preparar dicha composicion y uso del compuesto
ATE340155T1 (de) Medizinische anwendungen von phenylalkanolen und derivaten davon
AR014922A1 (es) Compuesto derivado de indol util en terapia, proceso para su preparacion, formulaciones farmaceuticas y procedimiento de tratamiento.
ES2154551B1 (es) Nuevos derivados de tetrazol como agentes antidiabeticos.
ATE505463T1 (de) Benzodiazepin-derivate, verwendbar als cck- rezeptor antagonisten
FI963645A0 (fi) Silmänpainetta alentava aine
NO169388C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 5-amino-1,2-ditiol-3-onderivater
TR200300359T4 (tr) İkameli yeni (dihidro)benzoksazin ve (dihidro)benzotiyazin türevleri bunların hazırlanma yöntemleri ve bunları içeren farmasötik bileşimler
ATE258934T1 (de) Azaindol derivate und ihre verwendung als antithrombotische wirkstoffe
DE69203732D1 (de) Substituierte Alkensäure und ihre Derivate.
ECSP972103A (es) Derivados indolicos utiles para terapia

Legal Events

Date Code Title Description
FA Abandonment or withdrawal